Prenatal folic acid supplementation improves long-term postnatal maternal cognitive performance: findings from a cohort study Authors: Jingjing Liu, Lanfang Zhao, Tuyan Fan, Wenjing Qiang, Tianli Zhu, Shuangqin Yan, Lanci Xie, Guopeng Gao, Hui Gao, Xiayan Yu, Kexin Gong, Yidan Cao, Fangbiao Tao, Beibei Zhu Published: 2026 ABSTRACT BackgroundFolic acid (FA) is a crucial component of the nervous system’s functions at all ages and is involved in a number of metabolic activities. We hypothesized that prenatal FA supplementation may profoundly affect women’s postnatal cognitive function, which has not been tested before.MethodsThis study was based on a cohort study (GDM follow-up study, GFS), which is a sub-cohort study derived from Ma’anshan Birth Cohort Study (MABC). A total of 182 women who had prenatal FA supplementation information and completed postnatal cognitive function tests were included in this study. FA supplementation data were prospectively collected in the 1st /2nd /3rd trimester of pregnancy by questionnaires. Cognitive functions were assessed with Stroop Color-Word Test (SCWT), Digit Symbol Substitution Test (DSST) and Montreal Cognitive Assessment (MoCA) in-person interviews conducted by qualified investigators at postpartum follow-up (the mean duration of postpartum follow-up of 7.9 (± 0.4) years). The associations between prenatal FA supplementation at different periods, cumulative FA supplementation, and early postnatal cognitive performance were investigated using linear regression models.ResultsAfter adjusting for confounding factors, FA supplementation during the 1st trimester of pregnancy (β = 9.15, 95%CI: 2.67 ~ 15.62, p = 0.006) and entire pregnancy (β = 8.88, 95%CI: 1.61 ~ 16.15, p = 0.017) were significantly associated with higher DSST scores. Supplementation of FA one month prior pregnancy was significantly associated with shorter Stroop Test A time (β= -0.67, 95%CI: -1.30~-0.05, p = 0.035), Stroop Test A time/Correct number (β= -0.03, 95%CI: -0.05 ~ 0.00, p = 0.036), and Stroop Test B time (β= -0.87, 95%CI: -1.73~-0.01, p = 0.047). Supplementation of FA during the 3rd trimester of pregnancy was significantly linked to shorter Stroop Test B time/Correct number (β= -0.06, 95%CI: -0.12 ~ 0.00, p = 0.048). FA supplementation during the entire pregnancy was associated with shorter Stroop Test B time (β= -1.95, 95%CI: -3.53~-0.37, p = 0.016), Stroop Test B time/Correct number (β= -0.09, 95%CI: -0.15~-0.02, p = 0.014). Furthermore, cognitive function scores increases progressively with longer periods of prenatal FA supplementation.ConclusionOur study is the first study suggested that FA supplementation from one month prior pregnancy to delivery could significantly improve maternal postpartum cognitive performance, and that the longer FA were taken, the greater benefit was likely to be.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12884-026-09272-1. Introduction The capacity of the human brain to organize newly acquired knowledge is referred to as cognitive function. Following the identification and integration of information, people process it to create a full understanding that enables them to solve issues and finish activities [1]. The cornerstones of cognitive development are memory, representational competence (the capacity to manipulate an image of an object or concept in the mind), attention, and processing speed [2, 3]. Tests of intelligence, attention, learning and memory, executive functions (such as working memory, cognitive flexibility, and inhibitory control), and speed of information processing were frequently used to evaluate cognitive ability [4]. Significant hormonal changes that occur during pregnancy and childbirth can cause cognitive impairment, as is frequently seen in postpartum women [5]. Previous research has shown that pregnant women have considerable impairments on certain memory tests, particularly those that require a high degree of executive cognitive control [6, 7], and these impairments may last into the postpartum period [8]. Therefore, it is crucial to identify beneficial factors that could improve women’s postnatal cognitive performance. Folic acid (FA), additionally referred to as vitamin B9, is a soluble in water vitamin that participates in the body’s purine and thymidylate biosynthesis, amino acid metabolism, oxidation reactions, and many other single-carbon transfer reactions. It is a vital requirement for the functioning of the nervous system throughout life [9]. During pregnancy, the growth of the fetus, placenta and changes in the mother’s physiological state all increase the demand for FA [10]. Taking FA supplements at the right time can alleviate FA deficiency and avoid health damage [11]. In most countries, it is recommended that women of reproductive age take FA supplements from preconception to the 12th week of pregnancy to prevent neural tube defects. The World Health Organization suggests that all women who are considering pregnancy or are capable of becoming pregnant should take 400–800 µg of FA daily [12]. Since 2009, China has included FA supplementation programs in basic public health services, recommending that women of reproductive age take 400 µg of FA daily from three months before pregnancy through the early stages of pregnancy [13]. Cognitive benefits of FA may be persist throughout various life-cycle stages [14]. A prospective cohort study found that FA intake below the recommended dietary levels in older women was associated with an increased risk of developing new-onset mild cognitive impairment over 5 years [15]. Additionally, the positive effects of FA supplementation during pregnancy on offspring cognitive performance are well-documented. Several studies utilizing self-reported FA data have identified a positive association between FA supplementation and cognitive performance in children [16–18]. The beneficial effects of FA during pregnancy on children’s cognitive development may even persist for up to 11 years postpartum [19]. According to an animal experiment, the extended use of dietary FA supplements reduced age-related reductions in cognitive function in Sprague-Dawley (SD) rats, achieved by reducing hippocampal shrinkage and increasing brain glucose absorption [20]. However, there are also inconsistent results. Two randomized controlled trials from the Netherlands and Australia have shown that neither a continuous supplementation of 400 µg of FA and 1000 µg of vitamin B-12 for 24 weeks [21] nor a continuous supplementation of 2 mg of FA, 400 µg of B12, and 25 mg of B6 for 2 years [22] has any beneficial effect on the cognitive function of the elderly. More importantly, most of these studies have been constrained to children and the elderly, and to our knowledge, its impact on postpartum females has not yet been evaluated. In this context, we aimed to assess if prenatal FA supplementation could profoundly improve women’s postnatal cognitive function. Therefore, based on a cohort study (GDM follow-up study, GFS), which is a sub-cohort study derived from Ma’anshan Birth Cohort Study (MABC), our goal was to investigate the impact of prenatal FA supplementation on long-term postnatal cognitive performance among women in their mid-thirties to early-forties to provide evidence for the prevention of cognitive decline in the postnatal period. Materials and methods Study population This study was based on the Ma’anshan Birth Cohort Study (MABC), a prospective cohort study based on the population. 3474 expectant mothers were progressively selected from the prenatal clinics of the Maternal and Child Health Care Centre in Ma’anshan, Anhui Province, China, between May 2013 and September 2014 [23]. To investigate long-term impact of gestational diabetes mellitus (GDM) on women’s health postpartum and the modifiable factors, from July 29, 2021 to August 23, 2022, a sub-cohort study—GDM follow-up study was established [24], of which 360 women (120 women with GDM history and 240 without it) received our invitations for follow-up, 335 agreed to participate and have been successfully. For our current study, 135 women without postnatal cognitive data (the cognitive testing was initiated on December 23, 2021; 135 women who were followed up prior to December 23), 4 with incomplete cognitive data, and 14 with missing data on prenatal FA supplementation were excluded, resulting in a final sample of 182 women (The detailed flowchart of participant selection is shown in Figure S1.). FA supplementation data were prospectively collected in the 1st /2nd /3rd trimester of pregnancy by questionnaires. Cognitive function was assessed at in-person interviews conducted by qualified investigators at postpartum follow-up (the mean duration of postpartum follow-up was 7.9 (± 0.4) years). Anhui Medical University’s ethical committee granted the study approval (20131401). For every subject, written informed permission was acquired. FA and multivitamin supplementation Information on the intake of multivitamins and FA by mothers was prospectively collected through self-administrated questionnaires [25] at the 1st, 2nd, and 3rd trimesters of pregnancy. By inquiring if they had used multivitamins or FA supplements during the four periods (one month before pregnancy, the 1st /2nd /3rd trimester of pregnancy) (e.g. Have you used the FA supplements a month before pregnancy? ), the information on their use was evaluated. If they replied regular use, participants were additionally asked about the frequency (e.g. daily, weekly). Women who took FA supplements or multivitamins for 1 ~ 2 days per week and above during any of these time periods were considered users of multivitamins or FA supplements for that specific period. The dose of FA was not collected, but local obstetricians recommend routine FA supplements at a dose of 400 µg per day. Furthermore, a FA supplementation score was calculated by summing the number of FA supplementation periods, where each period was assigned a score of 1 point if the supplementation was taken and 0 point if not. This scoring approach yielded five initial groups, corresponding to scores of 0, 1, 2, 3 and 4. However, given that only two people had score of 4, the two groups of 3 and 4 were merged, resulting in a final four-category variable (0, 1, 2, 3 ~ 4 points). Cognitive assessment We assessed maternal cognitive function during the postpartum follow-up. The cognitive function was assessed using Digit Symbol Substitution Test (DSST), Stroop Color-Word Test (SCWT) and Montreal Cognitive Assessment (MoCA). All the tests were conducted by trained research staff to make sure the reliability of assessments. The DSST test evaluated participants’ sustained attention, information processing speed, and working memory [26, 27]. The DSST is a cognitive test that is completed with paper and pencil on a single sheet of paper. Participants must match symbols to numbers using a key that is at the top of the page [28]. Within two minutes, participants had to accurately draw a set of symbols. Each participant received a single DSST score (the highest score is 100) based on the number of properly matched symbols, in accordance with the scoring standards. The higher score represented better cognitive function. The SCWT is a sensitive measure to differentiate individuals with and without cognitive decline [29]. The SCWT includes three subtests: word-reading (Stroop Test A), color-naming (Stroop Test B), and color-word (Stroop Test C) to assess processing speed, selective attention, perceptual switching, and response inhibitory capacity [30]. Stroop Test A and B primarily reflect the processing speed, selective attention, language fluency, and visual scanning abilities of the participants, while Stroop Test C mainly assesses the participants’ response inhibition capacity and perceptual switching [31, 32]. In Stroop Test A, participants will be asked to read aloud words printed in black ink. In Stroop Test B, they will be instructed to read aloud the color of colored circles. In Stroop Test C, they will be shown a page of color-words printed in incongruent colored ink. Participants will be asked to name the colour of ink used to print the words, omitting the word itself. There will be 24 items for each subtest. For each subtest, reaction time (measured in seconds) and correct number were individually recorded. Stroop Test A/B/C time and their ratios to the number of correct number are smaller, which means that the corresponding cognitive function is better. The MoCA measures global cognition and has good sensitivity for detecting cognitive decline [33]. The test evaluates seven cognitive domains: visuospatial/executive function, naming, attention, language (fluency), abstraction, delayed recall, and orientation. MoCA scores range from 0 to 30 points. Higher score indicate higher levels of cognitive function. If a participant has less than 12 years of education, 1 point is added to the total score. Covariates Detailed postpartum information was collected using a structured self-report questionnaire [24] at the postpartum follow-up for each participant. Detailed data included age, body mass index (BMI; in kg/m2), education, household income, marital status, parity, history of GDM, self-reported history of chronic diseases (type 2 diabetes, hypertension, other cardiovascular disease), depressive conditions, smoking behavior (never, ever, or current smoker), drinking behavior (never, ever, or current), FA supplementation in the past year (no supplementation, daily, weekly, monthly or yearly), pregnancy complications (e.g., GDM and hypertension during pregnancy, etc.), current medications for diseases (including hypertension, T2DM, hyperthyroidism and hypothyroidism). The BMI was calculated by dividing the weight (kg) by the square of the height (m). Education levels were divided into four categories: primary school and below, junior high school, high school, and college or above. Household income levels (Chinese Yuan) were divided into five groups: <50,000, 50,000 ~ 99,900, 100,000 ~ 199,000, 200,000 ~ 299,000, > 300,000. Marital status were divided into five groups: married, divorce, separate, unmarried, cohabit. Parity was divided into 1 and ≥ 2. Depressive disorders was assessed by the Patient Health Questionnaire 9 (PHQ-9) [34], and participants were divided into two groups: no depression (scores 0–4) and depression (scores ≥ 5). Data analysis Categorical variables are presented with percentages and frequencies. Continuous variables are presented as means ± SD. Confounding factors identified through literature review and biological plausibility. Coefficient (β) and 95% confidence interval (CI) was calculated from linear regression analyses adjusted for BMI, age, education, household income, marital status, parity, self-reported history of chronic diseases, depressive conditions, smoking and drinking status, multivitamin supplementation, FA supplementation in three time windows other than this period to investigate possible effects of FA supplementation in different periods and cumulative FA supplementation on the postnatal cognitive function. In addition, we conducted a stratified analysis based on the sex of the infants. Sensitivity analyses were conducted to test the stability of our results. First, 4 women who took FA supplements postpartum and 3 without data on postpartum FA supplements were excluded. Second, 8 women with pre-pregnancy thyroid disease were excluded. Third, multivitamin use for the corresponding period was excluded as a covariate. Data analyses were performed using the IBM SPSS Statistics 25.0. Every statistical test was run using a two-sided significance threshold of 0.05. Result Basic characteristics Table 1 displays the fundamental attributes of the participants who were included. A total of 182 women were included in the study. The average age of women was (35.91 ± 4.26) years and BMI was (23.42 ± 3.74) kg/m2. Half of women have education level of college and above, and most women never smoked (95.6%). Nearly one third women drink alcohol and over one third have parity ≥ 2, and 4.9% women live with chronic diseases. Table 1Characteristics of participants (n = 182)Basic characteristicsn (%) or means ± SDAge (years)35.91 ± 4.26BMI (kg/m2)23.42 ± 3.74Marriage Married175 (96.2) Other6 (3.3)Educational Primary school and below4 (2.2) Junior High School25 (13.7) High school/secondary school61 (33.5) College and above91 (50.0)Household income (10000 yuan) <527 (14.8) 5 ~9.9972 (39.6) 10 ~ 19.9954 (29.7) 20 ~ 29.9916 (8.8) ≥ 3012 (6.6)Smoking behavior Ever/current smoker7 (3.8) Never174 (95.6)Drinking behavior Ever/current drinker52 (28.6) Never129 (70.9)Depression Yes37 (20.5) No144 (79.5)Chronic diseases Yes9 (4.9) No172 (94.5)Parity 1104 (57.1) ≥ 270 (38.5)History of GDM Yes87 (47.8) No95 (52.2)BMI Body mass index, GDM Gestational diabetes mellitus Table 1Characteristics of participants (n = 182)Basic characteristicsn (%) or means ± SDAge (years)35.91 ± 4.26BMI (kg/m2)23.42 ± 3.74Marriage Married175 (96.2) Other6 (3.3)Educational Primary school and below4 (2.2) Junior High School25 (13.7) High school/secondary school61 (33.5) College and above91 (50.0)Household income (10000 yuan) <527 (14.8) 5 ~9.9972 (39.6) 10 ~ 19.9954 (29.7) 20 ~ 29.9916 (8.8) ≥ 3012 (6.6)Smoking behavior Ever/current smoker7 (3.8) Never174 (95.6)Drinking behavior Ever/current drinker52 (28.6) Never129 (70.9)Depression Yes37 (20.5) No144 (79.5)Chronic diseases Yes9 (4.9) No172 (94.5)Parity 1104 (57.1) ≥ 270 (38.5)History of GDM Yes87 (47.8) No95 (52.2)BMI Body mass index, GDM Gestational diabetes mellitus Characteristics of participants (n = 182) BMI Body mass index, GDM Gestational diabetes mellitus Association between FA supplementation at different periods and postnatal cognitive function The linear regression analysis’s findings on FA supplementation and cognitive function are shown in Table 2, Fig. 1, and Table S1-S3. After adjusting for confounding factors, compared with no FA supplementation, supplementation in the 1st trimester of pregnancy (β = 9.15, 95%CI: 2.67 ~ 15.62, p = 0.006) and the entire pregnancy (β = 8.88, 95%CI: 1.61 ~ 16.15, p = 0.017) were significantly associated with higher DSST scores (Table 2). Table 2Association between prenatal FA supplementation and DSST scoresSupplementN (%)Means (SDs)aβ(95%CI)aP valuebβ(95%CI)bP valueOne month before pregnancy < 0.001 0.181 No112 (61.5)81.3 ± 12.8RefRefYes70 (38.5)88.2 ± 12.16.86 (3.09, 10.64)2.61 (-1.22, 6.44)First trimester < 0.001 0.006 No16 (8.8)72.0 ± 11.0RefRef Yes166 (91.2)85.1 ± 12.613.08 (6.65, 19.52)9.15 (2.67, 15.62)Second trimester0.6860.850 No168 (92.3)83.8 ± 12.5RefRef Yes14 (7.7)85.3 ± 18.51.46 (-5.67, 8.60)-1.48 (-16.87, 13.91)Third trimester0.1750.082 No160 (87.9)83.5 ± 12.9RefRef Yes22 (12.1)87.5 ± 13.14.01 (-1.80, 9.81)5.46 (-0.71, 11.63)Entire pregnancy No13 (7.2)71.5 ± 11.9Ref < 0.001 Ref 0.017 Yes169 (92.8)84.9 ± 12.613.35 (6.23, 20.47)8.88 (1.61, 16.15)Note: Values in bold indicate p < 0.05aCrude modelbAdjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases (type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation for the corresponding period, FA supplementation in three time windows other than this period (for the entire pregnancy, FA supplementation one month before pregnancy was adjusted), pregnancy complications, and medications for diseases Table 2Association between prenatal FA supplementation and DSST scoresSupplementN (%)Means (SDs)aβ(95%CI)aP valuebβ(95%CI)bP valueOne month before pregnancy < 0.001 0.181 No112 (61.5)81.3 ± 12.8RefRefYes70 (38.5)88.2 ± 12.16.86 (3.09, 10.64)2.61 (-1.22, 6.44)First trimester < 0.001 0.006 No16 (8.8)72.0 ± 11.0RefRef Yes166 (91.2)85.1 ± 12.613.08 (6.65, 19.52)9.15 (2.67, 15.62)Second trimester0.6860.850 No168 (92.3)83.8 ± 12.5RefRef Yes14 (7.7)85.3 ± 18.51.46 (-5.67, 8.60)-1.48 (-16.87, 13.91)Third trimester0.1750.082 No160 (87.9)83.5 ± 12.9RefRef Yes22 (12.1)87.5 ± 13.14.01 (-1.80, 9.81)5.46 (-0.71, 11.63)Entire pregnancy No13 (7.2)71.5 ± 11.9Ref < 0.001 Ref 0.017 Yes169 (92.8)84.9 ± 12.613.35 (6.23, 20.47)8.88 (1.61, 16.15)Note: Values in bold indicate p < 0.05aCrude modelbAdjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases (type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation for the corresponding period, FA supplementation in three time windows other than this period (for the entire pregnancy, FA supplementation one month before pregnancy was adjusted), pregnancy complications, and medications for diseases Association between prenatal FA supplementation and DSST scores Note: Values in bold indicate p < 0.05 aCrude model bAdjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases (type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation for the corresponding period, FA supplementation in three time windows other than this period (for the entire pregnancy, FA supplementation one month before pregnancy was adjusted), pregnancy complications, and medications for diseases Fig. 1Association between prenatal FA supplementation and Stroop Test indicators. Adjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases (type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation for the corresponding period, FA supplementation in other three time windows (for the entire pregnancy, FA supplementation one month before pregnancy was adjusted), pregnancy complications, and medications for diseases.*: p < 0.05; **: p < 0.001 Association between prenatal FA supplementation and Stroop Test indicators. Adjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases (type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation for the corresponding period, FA supplementation in other three time windows (for the entire pregnancy, FA supplementation one month before pregnancy was adjusted), pregnancy complications, and medications for diseases.*: p < 0.05; **: p < 0.001 As shown in Fig. 1, in the fully adjusted model, FA supplementation one month prior pregnancy was significantly associated with shorter Stroop Test A time (β= -0.67, 95%CI: -1.30~-0.05, p = 0.035), Stroop Test A time/Correct number (β= -0.03, 95%CI: -0.05 ~ 0.00, p = 0.036), Stroop Test B time (β= -0.87, 95%CI: -1.73~-0.01, p = 0.047). Supplementation of FA in the 3rd trimester of pregnancy was significantly associated with shorter Stroop Test B time/Correct number (β= -0.06, 95%CI: -0.12 ~ 0.00, p = 0.048). FA supplementation during the entire pregnancy was associated with shorter Stroop Test B time (β= -1.95, 95%CI: -3.53~-0.37, p = 0.016), Stroop Test B time/Correct number (β= -0.09, 95%CI: -0.15~-0.02, p = 0.014) (Table S2-S3). In all five periods, compared with no FA supplementation, those having FA supplementation had higher MoCA scores, but the difference was not statistically significant (Table S1). Association of FA cumulative score with postnatal cognitive function The results of the multivariate linear regression analysis of FA cumulative score and postnatal cognitive indicators were shown in Fig. 2. Compared with individuals in the 0 point group, FA supplementation was found to be associated with better cognitive performance, and the cognitive function increased with the increasing FA cumulative score (All p for trend < 0.05). As for DSST scores, Stroop Test indicators, after adjusting for confounding factors, compared with 0 points group,1 points (β = 8.48; 95%CI: 1.06 ~ 15.91; p = 0.025), 2 points (β = 11.22; 95%CI: 3.53 ~ 18.91; p = 0.005) and 3 ~ 4 points group (β = 18.19; 95%CI: 7.78 ~ 28.60; p = 0.001) all had significantly higher DSST scores; and 1 points (β= -2.50; 95%CI: -4.12~-0.89; p = 0.003), 2 points (β= -3.06; 95%CI: -4.73~-1.39; p < 0.001) and 3 ~ 4 points group (β= -4.34; 95%CI: -6.60~-2.08; p < 0.001) all had significantly shorter Stroop Test B time; and 1 points (β= -0.11; 95%CI: -0.18~-0.04; p = 0.002), 2 points (β= -0.13; 95%CI: -0.20~-0.06; p < 0.001), and 3 ~ 4 points group (β= -0.19; 95%CI: -0.28~-0.09; p < 0.001) all had significantly lower Stroop Test B time/Correct number, and 3 ~ 4 points group had significantly lower Stroop Test C time (β= -5.84; 95%CI: -10.90~-0.78; p = 0.024); and 3 ~ 4 points group (β= -0.25; 95%CI: -0.48~-0.03; p = 0.025) had significantly lower Stroop Test C time/Correct number. Sensitivity analysis indicated the stability of the main analysis results (Tables S4-S6; Figure S2-S7). The stratified analysis suggests that the impact of FA supplementation on maternal postpartum cognitive function may vary by the sex of the offspring (Table S7, Figure S8 ~ S9). Fig. 2Association of cumulative FA use with cognitive indicators. Adjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases ((type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation throughout the period, pregnancy complications, and medications for diseases Association of cumulative FA use with cognitive indicators. Adjusted for age, BMI, education, household income, marital status, parity, self-reported history of chronic diseases ((type 2 diabetes, hypertension, cardiovascular disease), history of GDM, depressive conditions, smoking and drinking status, multivitamin supplementation throughout the period, pregnancy complications, and medications for diseases Discussion Our current study delved into the specific impact of prenatal FA supplementation on maternal cognitive functions at 7 to 8 years postpartum, while controlling for multiple confounding factors. We observed that supplementation of FA in the 1st trimester of pregnancy and entire pregnancy were significantly associated with higher sustained attention, information processing speed, and working memory abilities postpartum. Additionally, supplementation of FA one month prior pregnancy or in the 3rd trimester of pregnancy and entire pregnancy were closely related to better selective attention, language fluency, processing construction speed, and visual scanning abilities postpartum. Moreover, the longer FA were taken, the greater benefit was likely to be. FA is a class of heterocyclic compounds that comprises L-glutamic acids and 4-(pterin-6-methylamino) benzoic acid. Furthermore, it is a co-factor in the one-carbon metabolism (OCM) process, which is crucial for preserving the integrity of neurons and the flexibility of nerve cells [35, 36]. FA is significantly associated with several aspects of cognition [37, 38], particularly processing speed, memory and verbal fluency [39–41]. A study involving 211 healthy women across all age groups found that short-term FA supplementation (750 µg per day for 35 days) was associated with increased word memorization and recognition in middle-aged and older women. Additionally, higher dietary intake of FA was significantly correlated with processing speed, memory recall, and verbal fluency in women of all ages [40]. This is consistent with our findings. Our study indicated that prenatal FA supplementation was associated with significant improvements in processing speed, baseline attention, language fluency, and working memory capacity in the long-term postpartum period, as measured by DSST and SCWT. In all five periods, compared with no FA supplementation, those having FA supplementation had higher overall cognitive function (measured by the MoCA), but the difference was not statistically significant. This indicates that prenatal supplementation with FA may have significant benefits for specific (but not all) cognitive functions. In addition, the directness of the DSST and SCWT tests may better reflect the effects of FA supplementation. Alternatively, the insignificant results may be attributed to our relatively small sample size. Thus, it may be impossible to draw definitive conclusions, highlighting the need for studies with larger sample sizes for further investigation. The three cognitive assessments tools including DSST, Stroop, and MoCA we adopted provided comprehensive evidence for the link between prenatal FA supplementation and postpartum cognition, though we recognize more dimensions (e.g., memory, language) should be evaluated in the future work to gain a fuller picture. Pregnancy, as a female-specific life stage, involves a significant increase in maternal demand for DNA synthesis and chromatin methylation to support maternal metabolism and fetal growth and development, leading to a decrease in FA levels [42]. Consequently, FA supplementation is initiated during the periconceptional period to ensure an adequate reserve for the adjustment of maternal physiology [43]. During pregnancy, the overall cortical volume and thickness of a woman’s brain decrease [44, 45], thus has been defined as a unique period of neuroplasticity in adult life. While most network reductions may be readjusted or restored in the early postpartum period, some reductions in high-level cognitive networks may persist for longer periods, even extending up to 6 years postpartum [46]. In this context, the enduring positive effects of FA supplementation—a commonly used nutritional supplement—on women’s cognitive function during the critical period of pregnancy have become a question to be answered. However, to our knowledge, our study is the first population-based study to explore this topic. A previous experimental study in rats indicated that female mice supplemented with FA during gestation exhibited improved learning and memory abilities postpartum [47]. The results of this experiment suggest that FA supplementation during pregnancy in mice may promote effective communication between neurons and ultimately improve cognitive function by enhancing the expression of brain-derived neurotrophic factor (BDNF) in the maternal hippocampus, facilitating the generation of new neurons in the hippocampus, as well as improving synaptic plasticity and transmission efficiency [47]. Cumulative analyses demonstrated that effect sizes increased with higher cumulative FA scores. This implies that the benefit may be greater with a longer duration of adequate prenatal FA administration. Notably, our study did not find a significant effect of FA supplementation during the second trimester of pregnancy on postpartum cognition, which may be attributed to the hypothesis that FA has a sensitive period during pregnancy or to the relatively small number of pregnant women (14, 7.7%) who received FA supplementation during this period, thus the results should be interpreted with caution. In addition, excessive supplementation of FA can also pose some concerning potential issues, including the presence of unmetabolized folate in the blood circulation, increased cancer risks, and the masking of vitamin B-12 deficiency [48]. Therefore, future studies need more detailed information and larger sample size to validate our findings and determine the optimal dose of FA supplementation. There are several strengths to our study. To our knowledge, this is the first study explored the association between prenatal FA supplementation and their postnatal cognition, which highlights the novelty of our study. Second, the prospective cohort study design increased the credibility of our findings. Third, information on FA supplementation was collected during the 1st /2nd /3rd trimesters of pregnancy, thus largely avoided the recall bias. Fourth, our study conducted sensitivity analyses, and the results were relatively stable, indicating the reliability of our findings. Last, a spectrum of confounders were adjusted for in our study, granted high reliability of our findings. However, some limitations should also be noted. First, the lack of information on the dose of FA intake made us unable to explore how much amount of FA should take. Second, our study did not collect the dietary FA intake. Third, the interval between FA supplementation and cognitive testing was approximately 7 years postpartum, during which there are potentially a number of confounding factors that were not measured and could have influenced the results. Fourth, the study did not collect FA supplementation for pregnancies other than the one in 2013–2014, which may cause a misclassification bias. Fifth, given the exploratory nature of our study, no adjustments for multiple comparisons were applied to any statistical analyses performed. which may introduce the potential for false-positive findings, underscoring the need for future validation with larger samples. In addition, FA supplementation in this study was highly concentrated in the first trimester, with a very limited number of women supplementing during other periods. This distribution may impose constraints on statistical comparisons. Furthermore, this is an observational study; thus, causation cannot be inferred. Finally, this study has a relatively small sample size, and did not adjusted for the stress response related to childhood complications. Conclusion In conclusion, based on a prospective cohort study, we observed that FA supplementation from one month prior pregnancy to delivery was significantly associated with better postpartum cognitive performance, and that the longer FA were taken, the greater benefit was likely to be. Notably, due to the exploratory nature and the limited sample size of our study, the present findings can only serve as clues for future research. Future large-scale prospective cohort or randomized intervention studies are warranted to confirm these findings to provide evidence for developing strategy in improving postnatal cognitive function. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.